Clinical Trial

Redefine Study: A Study Evaluating the Efficacy, Safety, and Tolerability of COMP360 in Participants With Post-traumatic Stress Disorder

Study acronym: Redefine
Not Yet Recruiting Phase 2/3
View on ClinicalTrials.gov →
Summary
The Redefine Study (COMP202) is testing COMP360 to see if it may reduce post-traumatic stress disorder (PTSD) symptoms when administered alongside monitoring and support from a trained study team. COMP360 is a lab-made form of the naturally occurring chemical compound psilocybin.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2026-04-30.
Trial Details
NCT Number NCT07570654
Lead Sponsor COMPASS Pathways
Conditions PTSD - Post Traumatic Stress Disorder, PTSD, PTSD Symptoms, PTSD, Post Traumatic Stress Disorder
Enrollment 300 participants
Start Date 2026-09
Primary Completion 2028-11 (estimated)
Study Completion 2029-09 (estimated)
Updated on ClinicalTrials.gov 2026-05-12